Early relapse of follicular lymphoma may increase risk of death
the ONA take:
Early relapse of follicular lymphoma could be carefully considered when making decisions about treatment for these patients, according to a new study published online ahead of print in the Journal of Clinical Oncology.
Researchers at the University of Rochester in New York and colleagues analyzed data from the National LymphoCare Study in order to evaluate whether patients with follicular lymphoma who experience progression of disease within 2 years of initial R-CHOP therapy have an increased risk of death.
Results showed that the 5-year overall survival was 50% for those who experienced early progression of disease compared with 90% among those who did not.
"Through research we have confirmed that all relapsed patients are not equal, and therefore should not be approached the same at diagnosis nor at the time of relapse in terms of therapies," Carla Casulo, MD, oncologist and assistant professor of Medicine at the University of Rochester said.
Early relapse of follicular lymphoma could be carefully considered when making decisions about treatment for these patients.
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Compound in Teas, Peas, Soybeans May Increases Prostate Cancer Risk
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- A Case of Immunotherapy-Induced Myocarditis Concomitant to MG in Lung Cancer
- Online Learning Modules Improve Exercise Counseling, But Not Participation
- ASCO Issues Statement Addressing Alcohol and Cancer
- Duloxetine May Improve AI-Associated Joint Pain in Early Stage Breast Cancer
- Axillary Lymph Node Dissection Predictive for Lymphedema in Breast Cancer
- Drug Combination Does Not Extend Glioblastoma Survival
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|